ARTICLE | Clinical News
Xydalba dalbavancin regulatory update
February 2, 2015 8:00 AM UTC
EMA’s CHMP recommended approval of Xydalba dalbavancin from Actavis to treat acute bacterial skin and skin structure infections (ABSSSIs) in adults. The company markets the second-generation glycopept...